Androgel Trial Ends in AbbVie Win

Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

judge with gavel

AndroGel maker AbbVie has won its second jury verdict in a row. The manufacturer’s wins follow a jury ruling in March ordering the company to pay $3.2 million to a man injured by its testosterone replacement therapy.

A federal jury in Chicago handed up the most recent verdict June 14, 2018. Jurors found against plaintiff Robert Rowley.

Rowley, of Utah, blamed AndroGel for a blood clot he suffered in April 2013. He also blamed the drug for a second clot he suffered in late 2015.

Last month, another jury ruled against plaintiff Arthur Myers of Arizona. On June 13, 2018, Myers filed a motion for a new trial.

The cases are among more than 6,000 testosterone lawsuits pending in federal court. AbbVie says it faces about 200 more cases in various state courts.

The testosterone lawsuits were filed by men who blame Androgel for heart attacks, strokes and blood clots. The Androgel lawsuits are part of a larger multidistrict litigation (MDL) involving men who say they were harmed by testosterone replacement therapy (TRT) drugs.

Experiencing serious side effects from using testosterone therapy? Get a Free Case Review

Federal courts manage large numbers of lawsuits involving the same issues by way of MDLs. Under this arrangement, a single judge presides over all cases filed nationwide for pretrial matters. The MDL judge also presides over the first trials, known as bellwethers. Bellwether trials are intended to give parties guidance in settlement negotiations.

So far, the AndroGel trials have ended with mixed results. Two cases ended with verdicts in favor of patients. One jury ordered AbbVie to pay $140 million. Another jury ordered the drugmaker to pay $150 million. That larger verdict was overturned. A second trial in April 2018 ended in a verdict of $3.2 million.

Four other trials, including the most recent cases, ended in verdicts in favor of AbbVie. The latest verdict capped the sixth federal bellwether trial involving AndroGel injury claims.

U.S. District Judge Matthew F. Kennelly has scheduled 19 more AndroGel trials from Oct. 2, 2018, through March 4, 2019.

In May 2018, the judge dismissed about 160 cases when the plaintiffs failed to respond to requests for more information about their claims.

  •  
  •  
  •  

Did you find Drugwatch helpful?

9 Cited Research Articles

  1. AbbVie. (2018, March 31). Quarterly Report filed with United States Securities and Exchange Commission. Form 110-Q). Retrieved http://investors.abbvie.com/node/11691/html
  2. U.S. District Court for the Northern District of Illinois. (2015, March 30). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Master Short Form Complaint for Robert and Sherrie Rowley. Retrieved from http://www.pacer.gov
  3. U.S. District Court for the Northern District of Illinois. (2018, April 19). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Case Management Order 114. Retrieved from http://www.pacer.gov
  4. U.S. District Court for the Northern District of Illinois. (2018, June 13). Testosterone Replacement Therapy Products Liability Litigation. Case 1:14-cv-1085 Document # 69. Plaintiff’s Rule 59 Motion for a New Trial. Retrieved http://www.pacer.gov
  5. U.S. District Court for the Northern District of Illinois. (2018, May 11). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Stipulation of Dismissal without Prejudice. Document 2610. Retrieved from http://www.pacer.gov
  6. U.S. District Court for the Northern District of Illinois. (2018, May 11). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Stipulation of Dismissal with Prejudice. Document 2609. Retrieved from http://www.pacer.gov
  7. Jones, D.N. (2018, May 11) Dozens of Cases Cut from Testosterone Replacement MDL. Retrieved https://www.law360.com/articles/1042913/dozens-of-cases-cut-from-testosterone-replacement-mdl
  8. Jones, D.N. (2018, June 14). AbbVie Wind 5th Bellwether in Testosterone MDL. Retrieved https://www.law360.com/classaction/articles/1053802
  9. U.S. Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending. Retrieved http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-May-15-2018.pdf
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(844) 277-7079

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.